Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Tcr2 Therapeutics Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

  • $71.7 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 07, 2022
SELL
$4.58 - $8.34 $71,086 - $129,445
-15,521 Closed
0 $0
Q2 2021

Aug 06, 2021
BUY
$16.41 - $24.71 $46,309 - $69,731
2,822 Added 22.22%
15,521 $255,000
Q1 2021

May 06, 2021
BUY
$20.38 - $34.07 $81,744 - $136,654
4,011 Added 46.17%
12,699 $280,000
Q4 2020

Feb 09, 2021
BUY
$19.0 - $32.63 $165,072 - $283,489
8,688 New
8,688 $269,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email